#hepatocellular carcinoma

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.

Transplants due to hepatitis C have dropped dramatically, especially among people with liver cancer.

Those with NAFLD or NASH and cirrhosis should undergo regular screening.

Tecentriq plus Avastin improved both overall survival and patient-reported outcomes.

The LIVER Act would increase funding for liver cancer and hepatitis B research and prevention.

Smoking cessation, moderate drinking, a healthy diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer.

Successful treatment with direct-acting antivirals prolonged survival by 18 months.

People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.

Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.

People with liver cirrhosis often have substantial financial burden that interferes with their care.

October is Liver Cancer Awareness Month.

Those diagnosed with liver cancer after an HCV cure had a 66% lower risk of death.

Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.

Karen Hoyt promised her grandkids she would win a gold medal in the World Transplant Games. She wasn’t going to let HCC stand in her way.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.